Research & Development

Investment in R&D (2007: €788 million)

A world leader in antibody research

• SLAM technology to rapidly isolate functionally active antibodies
• Biological scaffolds to create more tolerable antibody-based therapies
• Pegylation to enhance the specificity and cost-efficiency of biologics

Unique and patented expertise in targeting the SV2A protein

• A large library of proprietary chemicals to unravel the role of SV2A in epilepsy and other diseases

Two Research Centres of Excellence

• Braine-l'Alleud (Belgium) covering CNS disorders
• Slough (UK) covering oncology/immunology, where UCB's R&D headquarters are located

The main development sites are in Atlanta (US), Braine-l'Alleud (Belgium), Monheim (Germany), Research Triangle Park (US), Slough (UK) and Tokyo (Japan)

Over thirty major R&D partnerships

• Includes Amgen (anti-sclerostin for bone loss disorders) and Biogen IDEC (CDP323 for multiple sclerosis)

An intellectual property estate of a large number of patent families